

Stephen I Rennard

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1393531/publications.pdf>

Version: 2024-02-01

302
papers

24,973
citations

7568

77
h-index

8167

148
g-index

378
all docs

378
docs citations

378
times ranked

19170
citing authors

#	ARTICLE	IF	CITATIONS
1	Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease. <i>New England Journal of Medicine</i> , 2010, 363, 1128-1138.	27.0	2,359
2	A Controlled Trial of Sustained-Release Bupropion, a Nicotine Patch, or Both for Smoking Cessation. <i>New England Journal of Medicine</i> , 1999, 340, 685-691.	27.0	1,495
3	Varenicline, an $\alpha 4\beta 2$ Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking Cessation<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>; <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 47.	7.4	1,231
4	Chronic Obstructive Pulmonary Disease Phenotypes. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 598-604.	5.6	898
5	Changes in Forced Expiratory Volume in 1 Second over Time in COPD. <i>New England Journal of Medicine</i> , 2011, 365, 1184-1192.	27.0	811
6	Persistent Systemic Inflammation is Associated with Poor Clinical Outcomes in COPD: A Novel Phenotype. <i>PLoS ONE</i> , 2012, 7, e37483.	2.5	633
7	The Safety and Efficacy of Infliximab in Moderate to Severe Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007, 175, 926-934.	5.6	393
8	Inflammatory Biomarkers Improve Clinical Prediction of Mortality in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 185, 1065-1072.	5.6	353
9	Efficacy and Safety of the Novel Selective Nicotinic Acetylcholine Receptor Partial Agonist, Varenicline, for Smoking Cessation. <i>Archives of Internal Medicine</i> , 2006, 166, 1571.	3.8	345
10	Genetic loci associated with chronic obstructive pulmonary disease overlap with loci for lung function and pulmonary fibrosis. <i>Nature Genetics</i> , 2017, 49, 426-432.	21.4	306
11	Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. <i>Lancet Respiratory Medicine</i> , the, 2018, 6, 117-126.	10.7	298
12	Design of the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS): Table 1. <i>Thorax</i> , 2014, 69, 492-495.	5.6	277
13	Airway Wall Thickening and Emphysema Show Independent Familial Aggregation in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 178, 500-505.	5.6	268
14	Six-Minute-Walk Test in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 187, 382-386.	5.6	257
15	Genetic landscape of chronic obstructive pulmonary disease identifies heterogeneous cell-type and phenotype associations. <i>Nature Genetics</i> , 2019, 51, 494-505.	21.4	257
16	Determinants of Depression in the ECLIPSE Chronic Obstructive Pulmonary Disease Cohort. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 183, 604-611.	5.6	250
17	Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD. <i>Respiratory Research</i> , 2011, 12, 18.	3.6	244
18	The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis from the ECLIPSE study. <i>Lancet Respiratory Medicine</i> , the, 2013, 1, 129-136.	10.7	224

#	ARTICLE	IF	CITATIONS
19	COPD: the dangerous underestimate of 15%. <i>Lancet, The</i> , 2006, 367, 1216-1219.	13.7	220
20	Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. <i>Lancet Respiratory Medicine</i> , 2017, 5, 619-626.	10.7	219
21	Antiinflammatory Effects of the Phosphodiesterase-4 Inhibitor Cilomilast (Ariflo) in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2003, 168, 976-982.	5.6	207
22	Effects of Varenicline on Smoking Cessation in Patients With Mild to Moderate COPD. <i>Chest</i> , 2011, 139, 591-599.	0.8	199
23	Comorbidities, Patient Knowledge, and Disease Management in a National Sample of Patients with COPD. <i>American Journal of Medicine</i> , 2009, 122, 348-355.	1.5	198
24	CXCR2 Antagonist MK-7123. A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 191, 1001-1011.	5.6	197
25	Fractional Processing of Sequential Bronchoalveolar Lavage to Separate Bronchial and Alveolar Samples. <i>The American Review of Respiratory Disease</i> , 1990, 141, 208-217.	2.9	193
26	Predicting Outcomes from 6-Minute Walk Distance in Chronic Obstructive Pulmonary Disease. <i>Journal of the American Medical Directors Association</i> , 2012, 13, 291-297.	2.5	193
27	Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. <i>Lancet, The</i> , 2009, 374, 712-719.	13.7	188
28	At the Root: Defining and Halting Progression of Early Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 1540-1551.	5.6	185
29	Efficacy and Safety of Budesonide and Formoterol in One Pressurized Metered-Dose Inhaler in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease. <i>Drugs</i> , 2008, 68, 1975-2000.	10.9	176
30	Reduced miR-146a Increases Prostaglandin E ₂ in Chronic Obstructive Pulmonary Disease Fibroblasts. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 1020-1029.	5.6	176
31	Early chronic obstructive pulmonary disease: definition, assessment, and prevention. <i>Lancet, The</i> , 2015, 385, 1778-1788.	13.7	176
32	Effect of Varenicline on Smoking Cessation Through Smoking Reduction. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 687.	7.4	173
33	Lung Fibroblast Repair Functions in Patients with Chronic Obstructive Pulmonary Disease Are Altered by Multiple Mechanisms. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 178, 248-260.	5.6	172
34	Efficacy and Tolerability of Budesonide/Formoterol in One Hydrofluoroalkane Pressurized Metered-Dose Inhaler in Patients with Chronic Obstructive Pulmonary Disease. <i>Drugs</i> , 2009, 69, 549-565.	10.9	171
35	Quantitative Computed Tomography Measures of Pectoralis Muscle Area and Disease Severity in Chronic Obstructive Pulmonary Disease. A Cross-Sectional Study. <i>Annals of the American Thoracic Society</i> , 2014, 11, 326-334.	3.2	168
36	An Official American Thoracic Society/European Respiratory Society Statement: Research Questions in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 191, e4-e27.	5.6	166

#	ARTICLE	IF	CITATIONS
37	Alternative Mechanisms for Long-Acting \hat{I}^{2} -Adrenergic Agonists in COPD. <i>Chest</i> , 2001, 120, 258-270.	0.8	156
38	Matrix metalloproteinase-9 activates TGF- \hat{I}^{2} and stimulates fibroblast contraction of collagen gels. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2014, 306, L1006-L1015.	2.9	156
39	Cells Derived from the Circulation Contribute to the Repair of Lung Injury. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004, 170, 1158-1163.	5.6	155
40	Pathogenesis of COPD. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2005, 26, 142-153.	2.1	155
41	Prostaglandin E ₂ inhibits fibroblast chemotaxis. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2001, 281, L1257-L1263.	2.9	145
42	Cigarette Smoke Inhibits Human Bronchial Epithelial Cell Repair Processes. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2001, 25, 772-779.	2.9	145
43	Are higher doses of nicotine replacement more effective for smoking cessation?. <i>Nicotine and Tobacco Research</i> , 1999, 1, 169-174.	2.6	139
44	Systemic Soluble Receptor for Advanced Glycation Endproducts Is a Biomarker of Emphysema and Associated with AGER Genetic Variants in Patients with Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 188, 948-957.	5.6	138
45	An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. <i>European Respiratory Journal</i> , 2015, 45, 879-905.	6.7	138
46	Evaluation of Elastase and Antielastase Balance in Patients with Chronic Bronchitis and Pulmonary Emphysema. <i>The American Review of Respiratory Disease</i> , 1990, 142, 57-62.	2.9	136
47	Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study. <i>Respiratory Research</i> , 2014, 15, 123.	3.6	130
48	Should We View Chronic Obstructive Pulmonary Disease Differently after ECLIPSE?. A Clinical Perspective from the Study Team. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 189, 1022-1030.	5.6	130
49	Long-term Safety and Efficacy of Indacaterol, a Long-Acting \hat{I}^{2} -Agonist, in Subjects With COPD. <i>Chest</i> , 2011, 140, 68-75.	0.8	126
50	Identification of Five Chronic Obstructive Pulmonary Disease Subgroups with Different Prognoses in the ECLIPSE Cohort Using Cluster Analysis. <i>Annals of the American Thoracic Society</i> , 2015, 12, 303-312.	3.2	126
51	Lessons from ECLIPSE: a review of COPD biomarkers. <i>Thorax</i> , 2014, 69, 666-672.	5.6	125
52	Augmentation of Functional Prostaglandin E Levels on the Respiratory Epithelial Surface by Aerosol Administration of Prostaglandin E. <i>The American Review of Respiratory Disease</i> , 1991, 144, 1080-1084.	2.9	121
53	Extended Therapy With Ipratropium Is Associated With Improved Lung Function in Patients With COPD. <i>Chest</i> , 1996, 110, 62-70.	0.8	117
54	TH2 Cytokine-enhanced and TGF- \hat{I}^{2} -enhanced vascular endothelial growth factor production by cultured human airway smooth muscle cells is attenuated by IFN- \hat{I}^{3} and corticosteroids. <i>Journal of Allergy and Clinical Immunology</i> , 2003, 111, 1307-1318.	2.9	117

#	ARTICLE	IF	CITATIONS
55	Cigarette Smoke Inhibits Alveolar Repair: A Mechanism for the Development of Emphysema. Proceedings of the American Thoracic Society, 2006, 3, 703-708.	3.5	114
56	Comparison of spatially matched airways reveals thinner airway walls in COPD. The Multi-Ethnic Study of Atherosclerosis (MESA) COPD Study and the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS). Thorax, 2014, 69, 987-996.	5.6	114
57	Regulation of fibroblast proliferation in three-dimensional collagen gel matrix. In Vitro Cellular and Developmental Biology - Animal, 1996, 32, 427-433.	1.5	106
58	Cilomilast for COPD. Chest, 2006, 129, 56-66.	0.8	105
59	The Breathlessness, Cough, and Sputum Scale. Chest, 2003, 124, 2182-2191.	0.8	104
60	Plasma Fibrinogen Qualification as a Drug Development Tool in Chronic Obstructive Pulmonary Disease. Perspective of the Chronic Obstructive Pulmonary Disease Biomarker Qualification Consortium. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 607-613.	5.6	104
61	The Many "Small COPDs". Chest, 2008, 134, 623-627.	0.8	102
62	Biomarkers Predictive of Exacerbations in the SPIROMICS and COPD Gene Cohorts. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 473-481.	5.6	101
63	A New Approach for Identifying Patients with Undiagnosed Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 748-756.	5.6	100
64	Cigarette Smoke Extract Induces DNA Damage but Not Apoptosis in Human Bronchial Epithelial Cells. American Journal of Respiratory Cell and Molecular Biology, 2005, 33, 121-129.	2.9	98
65	Smoking duration alone provides stronger risk estimates of chronic obstructive pulmonary disease than pack-years. Thorax, 2018, 73, 414-421.	5.6	96
66	Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPD. Chest, 2017, 151, 340-357.	0.8	91
67	Influence of diet and obesity on COPD development and outcomes. International Journal of COPD, 2014, 9, 723.	2.3	90
68	Treatment of stable chronic obstructive pulmonary disease. Lancet, The, 2004, 364, 791-802.	13.7	88
69	Common Genetic Polymorphisms Influence Blood Biomarker Measurements in COPD. PLoS Genetics, 2016, 12, e1006011.	3.5	88
70	Inflammation in COPD: Implications for Management. American Journal of Medicine, 2012, 125, 1162-1170.	1.5	86
71	PDE4 Inhibitors Attenuate Fibroblast Chemotaxis and Contraction of Native Collagen Gels. American Journal of Respiratory Cell and Molecular Biology, 2002, 26, 694-701.	2.9	85
72	Chronic Obstructive Pulmonary Disease Biomarker(s) for Disease Activity Needed "Urgently". American Journal of Respiratory and Critical Care Medicine, 2010, 182, 863-864.	5.6	85

#	ARTICLE	IF	CITATIONS
73	Bronchial Epithelial Cells Produce Lung Fibroblast Chemotactic Factor: Fibronectin. American Journal of Respiratory Cell and Molecular Biology, 1989, 1, 13-20.	2.9	84
74	Interleukin-4 and Interleukin-13 Enhanced Transforming Growth Factor- β 2 Production in Cultured Human Bronchial Epithelial Cells Is Attenuated by Interferon- β . American Journal of Respiratory Cell and Molecular Biology, 2002, 26, 484-490.	2.9	84
75	The future of chronic obstructive pulmonary disease treatment—difficulties of and barriers to drug development. Lancet, The, 2011, 378, 1027-1037.	13.7	84
76	The 6-Minute-Walk Distance Test as a Chronic Obstructive Pulmonary Disease Stratification Tool. Insights from the COPD Biomarker Qualification Consortium. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 1483-1493.	5.6	83
77	A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respiratory Medicine, 2008, 102, 1033-1044.	2.9	81
78	Human airway branch variation and chronic obstructive pulmonary disease. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E974-E981.	7.1	80
79	Reversible Cigarette Smoke Extract Induced DNA Damage in Human Lung Fibroblasts. American Journal of Respiratory Cell and Molecular Biology, 2004, 31, 483-490.	2.9	79
80	A Randomized Placebo-Controlled Trial of Varenicline for Smoking Cessation Allowing Flexible Quit Dates. Nicotine and Tobacco Research, 2012, 14, 343-350.	2.6	79
81	Chicken Soup Inhibits Neutrophil Chemotaxis In Vitro. Chest, 2000, 118, 1150-1157.	0.8	78
82	Targeting smokers at increased risk for relapse: treating women and those with a history of depression. Nicotine and Tobacco Research, 2003, 5, 99-109.	2.6	78
83	Identifying a gene expression signature of frequent COPD exacerbations in peripheral blood using network methods. BMC Medical Genomics, 2015, 8, 1.	1.5	78
84	Biomarkers to assess the utility of potential reduced exposure tobacco products. Nicotine and Tobacco Research, 2006, 8, 169-191.	2.6	77
85	Prognostic value of variables derived from the six-minute walk test in patients with COPD: Results from the ECLIPSE study. Respiratory Medicine, 2015, 109, 1138-1146.	2.9	77
86	Sarcopenic Obesity, Functional Outcomes, and Systemic Inflammation in Patients With Chronic Obstructive Pulmonary Disease. Journal of the American Medical Directors Association, 2016, 17, 712-718.	2.5	77
87	Plasma Fibrinogen as a Biomarker for Mortality and Hospitalized Exacerbations in People with COPD. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2014, 2, 23-34.	0.7	76
88	Smad3 mediates TGF- β 1 induction of VEGF production in lung fibroblasts. Biochemical and Biophysical Research Communications, 2005, 327, 393-398.	2.1	75
89	Biomarkers to assess the utility of potential reduced exposure tobacco products. Nicotine and Tobacco Research, 2006, 8, 599-622.	2.6	75
90	Complete Resolution of Roentgenographic Changes in a Patient with Pulmonary Histiocytosis X. Chest, 1990, 98, 765-767.	0.8	71

#	ARTICLE	IF	CITATIONS
91	Efficacy of the nicotine inhaler in smoking reduction: A double-blind, randomized trial. <i>Nicotine and Tobacco Research</i> , 2006, 8, 555-564.	2.6	67
92	The COPD Biomarker Qualification Consortium (CBQC). <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2013, 10, 367-377.	1.6	67
93	ORGANIC DUST TOXIC SYNDROME: AN ACUTE FEBRILE REACTION TO ORGANIC DUST EXPOSURE DISTINCT FROM HYPERSENSITIVITY PNEUMONITIS. <i>Journal of Toxicology: Clinical Toxicology</i> , 1990, 28, 389-420.	1.5	66
94	It's more than low BMI: prevalence of cachexia and associated mortality in COPD. <i>Respiratory Research</i> , 2019, 20, 100.	3.6	66
95	Cytokine Inhibition of Fibroblast-Induced Gel Contraction Is Mediated by PGE ₂ and NO Acting Through Separate Parallel Pathways. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2001, 25, 245-253.	2.9	65
96	The CC Chemokine Ligand 2 (CCL2) Mediates Fibroblast Survival through IL-6. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2007, 37, 121-128.	2.9	65
97	Vitamin D Modulates Prostaglandin E ₂ Synthesis and Degradation in Human Lung Fibroblasts. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2014, 50, 40-50.	2.9	65
98	Do COPD subtypes really exist? COPD heterogeneity and clustering in 10 independent cohorts. <i>Thorax</i> , 2017, 72, 998-1006.	5.6	65
99	Th2 cytokine regulation of type I collagen gel contraction mediated by human lung mesenchymal cells. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2002, 282, L1049-L1056.	2.9	64
100	Deterioration of Limb Muscle Function during Acute Exacerbation of Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 433-449.	5.6	64
101	MicroRNA-146a modulates human bronchial epithelial cell survival in response to the cytokine-induced apoptosis. <i>Biochemical and Biophysical Research Communications</i> , 2009, 380, 177-182.	2.1	61
102	Efficacy of Varenicline to Prompt Quit Attempts in Smokers Not Currently Trying to Quit: A Randomized Placebo-Controlled Trial. <i>Nicotine and Tobacco Research</i> , 2011, 13, 955-964.	2.6	60
103	Determinants of Response to Roflumilast in Severe Chronic Obstructive Pulmonary Disease. Pooled Analysis of Two Randomized Trials. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 1268-1278.	5.6	60
104	Proposal for a multidimensional staging system for chronic obstructive pulmonary disease. <i>Respiratory Medicine</i> , 2005, 99, 1546-1554.	2.9	59
105	Natural Histories of Chronic Obstructive Pulmonary Disease. <i>Proceedings of the American Thoracic Society</i> , 2008, 5, 878-883.	3.5	59
106	Smad3 mediates TGF- β 1-induced collagen gel contraction by human lung fibroblasts. <i>Biochemical and Biophysical Research Communications</i> , 2006, 339, 290-295.	2.1	58
107	NF-kappaB mediates the survival of human bronchial epithelial cells exposed to cigarette smoke extract. <i>Respiratory Research</i> , 2008, 9, 66.	3.6	58
108	A Simplified Score to Quantify Comorbidity in COPD. <i>PLoS ONE</i> , 2014, 9, e114438.	2.5	58

#	ARTICLE	IF	CITATIONS
109	What have we learned from large drug treatment trials in COPD?. <i>Lancet, The</i> , 2007, 370, 774-785.	13.7	57
110	Modulation of Fibronectin Production of Bovine Bronchial Epithelial Cells by Transforming Growth Factor- β . <i>American Journal of Respiratory Cell and Molecular Biology</i> , 1992, 7, 149-155.	2.9	54
111	Exacerbations and Progression of Disease in Asthma and Chronic Obstructive Pulmonary Disease. <i>Proceedings of the American Thoracic Society</i> , 2004, 1, 88-92.	3.5	54
112	Serum-free culture of fractionated bovine bronchial epithelial cells. <i>In Vitro Cellular & Developmental Biology</i> , 1992, 28, 39-46.	1.0	53
113	Chest computed tomography-derived low-fat-free mass index and mortality in COPD. <i>European Respiratory Journal</i> , 2017, 50, 1701134.	6.7	53
114	Exome Array Analysis Identifies a Common Variant in <i>IL27</i> Associated with Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 48-57.	5.6	52
115	Treatment of Chronic Obstructive Pulmonary Disease with Roflumilast, a New Phosphodiesterase 4 Inhibitor. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2010, 7, 141-153.	1.6	51
116	Reactive Nitrogen Species Augment Fibroblast-Mediated Collagen Gel Contraction, Mediator Production, and Chemotaxis. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2006, 34, 592-599.	2.9	50
117	Chest CT Measures of Muscle and Adipose Tissue in COPD. <i>Academic Radiology</i> , 2014, 21, 1255-1261.	2.5	50
118	One-year change in health status and subsequent outcomes in COPD. <i>Thorax</i> , 2015, 70, 420-425.	5.6	50
119	The Relationship between Dietary Fiber Intake and Lung Function in the National Health and Nutrition Examination Surveys. <i>Annals of the American Thoracic Society</i> , 2016, 13, 643-650.	3.2	49
120	The Efficacy and Safety of Cilomilast in COPD. <i>Drugs</i> , 2008, 68, 3-57.	10.9	48
121	Sexually-dimorphic targeting of functionally-related genes in COPD. <i>BMC Systems Biology</i> , 2014, 8, 118.	3.0	47
122	Cultured Lung Fibroblasts from Ovalbumin-Challenged "Asthmatic" Mice Differ Functionally from Normal. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2007, 37, 424-430.	2.9	45
123	N-acetyl-l-cysteine inhibits TGF- β 1-induced profibrotic responses in fibroblasts. <i>Pulmonary Pharmacology and Therapeutics</i> , 2009, 22, 487-491.	2.6	45
124	Introducing the COPD Foundation Guide for Diagnosis and Management of COPD, Recommendations of the COPD Foundation. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2013, 10, 378-389.	1.6	45
125	Activation of protein kinase A accelerates bovine bronchial epithelial cell migration. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2002, 282, L1108-L1116.	2.9	44
126	Cigarette Smoke in Research. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2004, 31, 479-480.	2.9	44

#	ARTICLE	IF	CITATIONS
127	Machine Learning Characterization of COPD Subtypes. <i>Chest</i> , 2020, 157, 1147-1157.	0.8	44
128	Genetic control of gene expression at novel and established chronic obstructive pulmonary disease loci. <i>Human Molecular Genetics</i> , 2015, 24, 1200-1210.	2.9	43
129	Transforming Growth Factor- β Stimulates the Expression of Desmosomal Proteins in Bronchial Epithelial Cells. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 1992, 6, 439-445.	2.9	42
130	Nerve growth factor stimulates fibronectin-induced fibroblast migration. <i>Translational Research</i> , 2002, 140, 329-335.	2.3	42
131	Cytotoxicity and gene expression changes induced by inorganic and organic trivalent arsenicals in human cells. <i>Toxicology</i> , 2013, 312, 18-29.	4.2	42
132	The development of AZD7624 for prevention of exacerbations in COPD: a randomized controlled trial. <i>International Journal of COPD</i> , 2018, Volume 13, 1009-1019.	2.3	42
133	The Bronchitis Index. <i>Chest</i> , 1993, 103, 1482-1488.	0.8	41
134	Design of a multi-center immunophenotyping analysis of peripheral blood, sputum and bronchoalveolar lavage fluid in the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS). <i>Journal of Translational Medicine</i> , 2015, 13, 19.	4.4	41
135	Age-Related Differences in Health-Related Quality of Life in COPD. <i>Chest</i> , 2016, 149, 927-935.	0.8	41
136	Looking at the Patient "Approaching the Problem of COPD. <i>New England Journal of Medicine</i> , 2004, 350, 965-966.	27.0	40
137	Human bronchial epithelial cells modulate collagen gel contraction by fibroblasts. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 1998, 274, L119-L126.	2.9	39
138	ACCORD COPD II: A Randomized Clinical Trial to Evaluate the 12-Week Efficacy and Safety of Twice-Daily Acclidinium Bromide in Chronic Obstructive Pulmonary Disease Patients. <i>Clinical Drug Investigation</i> , 2013, 33, 893-904.	2.2	39
139	Smad3 mediates the TGF- β -induced contraction of type I collagen gels by mouse embryo fibroblasts. <i>Cytoskeleton</i> , 2003, 54, 248-253.	4.4	38
140	Glucocorticoids modulate TGF-beta production. <i>Inflammation</i> , 2002, 26, 279-290.	3.8	37
141	Glutathione prevents inhibition of fibroblast-mediated collagen gel contraction by cigarette smoke. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2002, 283, L409-L417.	2.9	36
142	Persistent and Newly Developed Chronic Bronchitis Are Associated with Worse Outcomes in Chronic Obstructive Pulmonary Disease. <i>Annals of the American Thoracic Society</i> , 2016, 13, 1016-1025.	3.2	36
143	Chronic Obstructive Pulmonary Disease: Linking Outcomes and Pathobiology of Disease Modification. <i>Proceedings of the American Thoracic Society</i> , 2006, 3, 276-280.	3.5	34
144	Fibroblasts that resist cigarette smoke-induced senescence acquire profibrotic phenotypes. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2014, 307, L364-L373.	2.9	34

#	ARTICLE	IF	CITATIONS
145	Cigarette smoke extract inhibits chemotaxis and collagen gel contraction mediated by human bone marrow osteoprogenitor cells and osteoblast-like cells. <i>Osteoporosis International</i> , 2003, 14, 235-242.	3.1	33
146	Clinical Approach to Patients with Chronic Obstructive Pulmonary Disease and Cardiovascular Disease. <i>Proceedings of the American Thoracic Society</i> , 2005, 2, 94-100.	3.5	33
147	Glucocorticoids modulate TGF-beta production by human fetal lung fibroblasts. <i>Inflammation</i> , 2003, 27, 9-19.	3.8	32
148	Patients with Chronic Obstructive Pulmonary Disease Walk with Altered Step Time and Step Width Variability as Compared with Healthy Control Subjects. <i>Annals of the American Thoracic Society</i> , 2017, 14, 858-866.	3.2	32
149	Whole exome sequencing analysis in severe chronic obstructive pulmonary disease. <i>Human Molecular Genetics</i> , 2018, 27, 3801-3812.	2.9	32
150	Bronchoalveolar Lavage Fluid from COPD Patients Reveals More Compounds Associated with Disease than Matched Plasma. <i>Metabolites</i> , 2019, 9, 157.	2.9	32
151	Fibronectin production by cultured human lung fibroblasts in three-dimensional collagen gel culture. <i>In Vitro Cellular and Developmental Biology - Animal</i> , 1998, 34, 203-210.	1.5	31
152	Evaluation of subclinical respiratory tract inflammation in heavy smokers who switch to a cigarette-like nicotine delivery device that primarily heats tobacco. <i>Nicotine and Tobacco Research</i> , 2002, 4, 467-476.	2.6	31
153	Effect of cigarette smoke on fibroblast-mediated gel contraction is dependent on cell density. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2003, 284, L205-L213.	2.9	31
154	Prostacyclin analogs stimulate VEGF production from human lung fibroblasts in culture. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2008, 294, L1226-L1232.	2.9	31
155	Network-based analysis reveals novel gene signatures in peripheral blood of patients with chronic obstructive pulmonary disease. <i>Respiratory Research</i> , 2017, 18, 72.	3.6	31
156	Retinoic Acid Attenuates Cytokine-Driven Fibroblast Degradation of Extracellular Matrix in Three-Dimensional Culture. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2001, 25, 620-627.	2.9	30
157	Respiratory Symptoms Items from the COPD Assessment Test Identify Ever-Smokers with Preserved Lung Function at Higher Risk for Poor Respiratory Outcomes. An Analysis of the Subpopulations and Intermediate Outcome Measures in COPD Study Cohort. <i>Annals of the American Thoracic Society</i> , 2017, 14, 636-642.	3.2	30
158	Chronic Bronchitis and Emphysema. , 2010, , 919-967.		30
159	Glucocorticoids Augment Fibroblast-Mediated Contraction of Collagen Gels by Inhibition of Endogenous PGE Production. <i>Proceedings of the Association of American Physicians</i> , 1999, 111, 249-258.	2.0	30
160	Cigarette Smoke Stimulates Release of Neutrophil Chemotactic Activity from Cultured Bovine Bronchial Epithelial Cells. <i>Clinical Science</i> , 1995, 88, 337-344.	4.3	29
161	TGF- β 1 and serum both stimulate contraction but differentially affect apoptosis in 3D collagen gels. <i>Respiratory Research</i> , 2005, 6, 141.	3.6	29
162	Determinants of exercise-induced oxygen desaturation including pulmonary emphysema in COPD: Results from the ECLIPSE study. <i>Respiratory Medicine</i> , 2016, 119, 87-95.	2.9	29

#	ARTICLE	IF	CITATIONS
163	Integrative Genomics of Emphysema-Associated Genes Reveals Potential Disease Biomarkers. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2017, 57, 411-418.	2.9	28
164	A randomised double-blind, placebo-controlled, long-term extension study of the efficacy, safety and tolerability of fixed-dose combinations of aclidinium/formoterol or monotherapy in the treatment of chronic obstructive pulmonary disease. <i>Respiratory Medicine</i> , 2017, 125, 39-48.	2.9	28
165	Glucocorticoids and TGF-beta1 synergize in augmenting fibroblast mediated contraction of collagen gels. <i>Inflammation</i> , 2001, 25, 109-117.	3.8	27
166	Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in COPD. <i>Respiratory Medicine</i> , 2011, 105, 1176-1188.	2.9	27
167	Relationship between Emphysema Progression at CT and Mortality in Ever-Smokers: Results from the COPDgene and ECLIPSE Cohorts. <i>Radiology</i> , 2021, 299, 222-231.	7.3	27
168	Localization of the human fibronectin (FN) gene on chromosome 8 by a specific enzyme immunoassay. <i>Biochemical Genetics</i> , 1981, 19, 551-566.	1.7	26
169	Prostacyclin Analogs Inhibit Fibroblast Contraction of Collagen Gels through the cAMP-PKA Pathway. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2007, 37, 113-120.	2.9	26
170	Systemic inflammatory profile and response to anti-tumor necrosis factor therapy in chronic obstructive pulmonary disease. <i>Respiratory Research</i> , 2012, 13, 12.	3.6	26
171	Simultaneous LC-MS/MS analysis of eicosanoids and related metabolites in human serum, sputum and BALF. <i>Biomedical Chromatography</i> , 2018, 32, e4102.	1.7	26
172	Markers of disease activity in COPD: an 8-year mortality study in the ECLIPSE cohort. <i>European Respiratory Journal</i> , 2021, 57, 2001339.	6.7	26
173	Prostaglandin E2 Inhibits Human Lung Fibroblast Chemotaxis through Disparate Actions on Different E-Prostanoid Receptors. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2011, 44, 99-107.	2.9	25
174	Imaging-based clusters in former smokers of the COPD cohort associate with clinical characteristics: the SubPopulations and intermediate outcome measures in COPD study (SPIROMICS). <i>Respiratory Research</i> , 2019, 20, 153.	3.6	25
175	Prostaglandin E ₂ Stimulates the Production of Vascular Endothelial Growth Factor through the E-Prostanoid ² Receptor in Cultured Human Lung Fibroblasts. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2012, 46, 217-223.	2.9	24
176	Upregulation of RGS2: a new mechanism for pirfenidone amelioration of pulmonary fibrosis. <i>Respiratory Research</i> , 2016, 17, 103.	3.6	24
177	Objectively Measured Physical Activity in Patients with COPD: Recommendations from an International Task Force on Physical Activity. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2021, 8, 528-550.	0.7	24
178	Cytopathology of Opportunistic Infection in Bronchoalveolar Lavage. <i>American Journal of Clinical Pathology</i> , 1987, 88, 421-428.	0.7	23
179	Selective Migration of α -Smooth Muscle Actin-Positive Myofibroblasts toward Fibronectin in the Boyden's Blindwell Chamber. <i>Clinical Science</i> , 1997, 93, 355-362.	4.3	23
180	Prostaglandin E2 protects human lung fibroblasts from cigarette smoke extract-induced apoptosis via EP2 receptor activation. <i>Journal of Cellular Physiology</i> , 2007, 210, 99-110.	4.1	23

#	ARTICLE	IF	CITATIONS
181	Randomized study of the safety, pharmacokinetics, and bronchodilatory efficacy of a proprietary glycopyrronium metered-dose inhaler in study patients with chronic obstructive pulmonary disease. <i>BMC Pulmonary Medicine</i> , 2014, 14, 118.	2.0	23
182	Rationale and Emerging Approaches for Targeting Lung Repair and Regeneration in the Treatment of Chronic Obstructive Pulmonary Disease. <i>Proceedings of the American Thoracic Society</i> , 2011, 8, 368-375.	3.5	22
183	Smad3 mediates cigarette smoke extract (CSE) induction of VEGF release by human fetal lung fibroblasts. <i>Toxicology Letters</i> , 2013, 220, 126-134.	0.8	22
184	Persistent systemic inflammation and symptoms of depression among patients with COPD in the ECLIPSE cohort. <i>Respiratory Medicine</i> , 2014, 108, 1647-1654.	2.9	22
185	Smoking Cessation. <i>Clinics in Chest Medicine</i> , 2014, 35, 165-176.	2.1	22
186	Seven Pillars of Small Airways Disease in Asthma and COPD. <i>Chest</i> , 2021, 160, 114-134.	0.8	22
187	The 2017 Update to the COPD Foundation COPD Pocket Consultant Guide. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2017, 4, 177-185.	0.7	22
188	Modification of Type I Collagenous Gels by Alveolar Epithelial Cells. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2000, 22, 702-707.	2.9	21
189	Chronic Obstructive Pulmonary Disease: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases. <i>Annals of the American Thoracic Society</i> , 2014, 11, S154-S160.	3.2	21
190	Radiological correlates and clinical implications of the paradoxical lung function response to $\hat{I}2$ agonists: an observational study. <i>Lancet Respiratory Medicine</i> , the, 2014, 2, 911-918.	10.7	21
191	Gait mechanics in patients with chronic obstructive pulmonary disease. <i>Respiratory Research</i> , 2015, 16, 31.	3.6	21
192	Interpreting patient-reported outcomes from clinical trials in COPD: a discussion. <i>International Journal of COPD</i> , 2016, Volume 11, 3069-3078.	2.3	21
193	Use of a 4-week up-titration regimen of roflumilast in patients with severe COPD. <i>International Journal of COPD</i> , 2018, Volume 13, 813-822.	2.3	21
194	Elevation of chemotactic factor inactivator in alcoholic liver disease. <i>Hepatology</i> , 1987, 7, 872-877.	7.3	20
195	Long-term safety study of infliximab in moderate-to-severe chronic obstructive pulmonary disease. <i>Respiratory Medicine</i> , 2013, 107, 424-432.	2.9	20
196	Imaging-based clusters in current smokers of the COPD cohort associate with clinical characteristics: the SubPopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS). <i>Respiratory Research</i> , 2018, 19, 178.	3.6	20
197	Variability in objective and subjective measures affects baseline values in studies of patients with COPD. <i>PLoS ONE</i> , 2017, 12, e0184606.	2.5	20
198	St George's Respiratory Questionnaire Score Predicts Outcomes in Patients with COPD: Analysis of Individual Patient Data in the COPD Biomarkers Qualification Consortium Database. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2017, 4, 137-145.	0.7	20

#	ARTICLE	IF	CITATIONS
199	Human bronchial epithelial cells can contract type I collagen gels. American Journal of Physiology - Lung Cellular and Molecular Physiology, 1998, 274, L58-L65.	2.9	19
200	PGD2 Modulates Fibroblast-Mediated Native Collagen Gel Contraction. American Journal of Respiratory Cell and Molecular Biology, 2002, 27, 375-381.	2.9	19
201	COPD Exacerbation Biomarkers Validated Using Multiple Reaction Monitoring Mass Spectrometry. PLoS ONE, 2016, 11, e0161129.	2.5	19
202	Lower respiratory tract inflammation in grain farmers. American Journal of Industrial Medicine, 1990, 17, 75-76.	2.1	18
203	The Effect of Different Case Definitions of Current Smoking on the Discovery of Smoking-Related Blood Gene Expression Signatures in Chronic Obstructive Pulmonary Disease. Nicotine and Tobacco Research, 2016, 18, 1903-1909.	2.6	18
204	Safety and Tolerability of Comprehensive Research Bronchoscopy in Chronic Obstructive Pulmonary Disease. Results from the SPIROMICS Bronchoscopy Substudy. Annals of the American Thoracic Society, 2019, 16, 439-446.	3.2	18
205	COPD: treatments benefit patients. Lancet, The, 2003, 361, 444-445.	13.7	17
206	Minimal Clinically Important Difference, Clinical Perspective: An Opinion. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2005, 2, 51-55.	1.6	17
207	Inflammatory cytokines regulate endothelial cell survival and tissue repair functions via NF- κ B signaling. Journal of Inflammation Research, 2011, 4, 127.	3.5	17
208	Small airway determinants of airflow limitation in chronic obstructive pulmonary disease. Thorax, 2021, 76, 1079-1088.	5.6	17
209	Objectively Measured Physical Activity as a COPD Clinical Trial Outcome. Chest, 2021, 160, 2080-2100.	0.8	17
210	Hepatic growth factor (HGF) inhibits cigarette smoke extract induced apoptosis in human bronchial epithelial cells. Experimental Cell Research, 2010, 316, 3501-3511.	2.6	16
211	Differentiation of embryonic stem cells into fibroblast-like cells in three-dimensional type I collagen gel cultures. In Vitro Cellular and Developmental Biology - Animal, 2011, 47, 114-124.	1.5	16
212	COPD Heterogeneity: What This Will Mean in Practice. Respiratory Care, 2011, 56, 1181-1187.	1.6	16
213	The Effect of Statins on Blood Gene Expression in COPD. PLoS ONE, 2015, 10, e0140022.	2.5	16
214	Effect of culture conditions on microRNA expression in primary adult control and COPD lung fibroblasts in vitro. In Vitro Cellular and Developmental Biology - Animal, 2015, 51, 390-399.	1.5	16
215	Prostaglandin E2 switches from a stimulator to an inhibitor of cell migration after epithelial-to-mesenchymal transition. Prostaglandins and Other Lipid Mediators, 2015, 116-117, 1-9.	1.9	16
216	Postdeployment Respiratory Syndrome in Soldiers With Chronic Exertional Dyspnea. American Journal of Surgical Pathology, 2021, 45, 1587-1596.	3.7	16

#	ARTICLE	IF	CITATIONS
217	Reduced microRNA-503 expression augments lung fibroblast VEGF production in chronic obstructive pulmonary disease. PLoS ONE, 2017, 12, e0184039.	2.5	16
218	MicroRNAs as Therapeutic Targets in Lung Disease: Prospects and Challenges. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2016, 3, 382-388.	0.7	16
219	COPD in 2001. Chest, 2002, 121, 113S-115S.	0.8	15
220	The Promise of Observational Studies (ECLIPSE, SPIROMICS, and COPDGene) in Achieving the Goal of Personalized Treatment of Chronic Obstructive Pulmonary Disease. Seminars in Respiratory and Critical Care Medicine, 2015, 36, 478-490.	2.1	15
221	TGF- β ² induces a heart failure phenotype via fibroblasts exosome signaling. Heliyon, 2019, 5, e02633.	3.2	15
222	Turning a Molecule into a Medicine: the Development of Indacaterol as a Novel Once-Daily Bronchodilator Treatment for Patients with COPD. Drugs, 2014, 74, 1635-1657.	10.9	14
223	Understanding the impact of second-hand smoke exposure on clinical outcomes in participants with COPD in the SPIROMICS cohort. Thorax, 2016, 71, 411-420.	5.6	14
224	Viral Infection of Bovine Bronchial Epithelial Cells Induces Increased Neutrophil Chemotactic Activity and Neutrophil Adhesion. Clinical Science, 1993, 85, 753-760.	4.3	13
225	Cytokines modulate cilomilast response in lung fibroblasts. Clinical Immunology, 2004, 111, 297-302.	3.2	13
226	Reprogramming of COPD lung fibroblasts through formation of induced pluripotent stem cells. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2014, 306, L552-L565.	2.9	13
227	Body mass index change in gastrointestinal cancer and chronic obstructive pulmonary disease is associated with Dedicator of Cytokines 1. Journal of Cachexia, Sarcopenia and Muscle, 2017, 8, 428-436.	7.3	13
228	Overview of causes of COPD. Postgraduate Medicine, 2002, 111, 28-38.	2.0	12
229	Efficacy of a flexible quit date versus an a priori quit date approach to smoking cessation: A cross-study analysis. Addictive Behaviors, 2011, 36, 1288-1291.	3.0	12
230	Continuous fat-free mass decline in COPD: fact or fiction?. European Respiratory Journal, 2015, 46, 1496-1498.	6.7	12
231	Alveolar eosinophilia in current smokers with chronic obstructive pulmonary disease in the SPIROMICS cohort. Journal of Allergy and Clinical Immunology, 2018, 141, 429-432.	2.9	12
232	Can CAPTURE be used to identify undiagnosed patients with mild-to-moderate COPD likely to benefit from treatment?. International Journal of COPD, 2018, Volume 13, 1901-1912.	2.3	12
233	Chicken Soup in the Time of COVID. Chest, 2020, 158, 864-865.	0.8	12
234	Latent traits of lung tissue patterns in former smokers derived by dual channel deep learning in computed tomography images. Scientific Reports, 2021, 11, 4916.	3.3	12

#	ARTICLE	IF	CITATIONS
235	Induction of bovine bronchial epithelial cell filopodia by tetradecanoyl phorbol acetate, calcium ionophore, and lysophosphatidic acid. <i>Journal of Cellular Physiology</i> , 1995, 164, 123-131.	4.1	11
236	Effect of Initial Collagen Concentration on Fibroblast Mediated Contraction of Collagen Gels. <i>Chest</i> , 2000, 117, 234S-235S.	0.8	11
237	Phosphodiesterase-4 Inhibition Augments Human Lung Fibroblast Vascular Endothelial Growth Factor Production Induced by Prostaglandin E ₂ . <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2013, 49, 571-581.	2.9	11
238	Roflumilast and dyspnea in patients with moderate to very severe chronic obstructive pulmonary disease: a pooled analysis of four clinical trials. <i>International Journal of COPD</i> , 2014, 9, 657.	2.3	11
239	Clinical and prognostic heterogeneity of C and D GOLD groups. <i>European Respiratory Journal</i> , 2015, 46, 250-254.	6.7	11
240	Diagnosis and management of asthma, COPD and asthma-COPD overlap among primary care physicians and respiratory/allergy specialists: A global survey. <i>Clinical Respiratory Journal</i> , 2019, 13, 355-367.	1.6	11
241	Agonist-specific desensitization of PGE ₂ -stimulated cAMP signaling due to upregulated phosphodiesterase expression in human lung fibroblasts. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2020, 393, 843-856.	3.0	11
242	Genetic variation in genes regulating skeletal muscle regeneration and tissue remodelling associated with weight loss in chronic obstructive pulmonary disease. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 1803-1817.	7.3	11
243	Grain dusts and grain plant components vary in their ability to recruit neutrophils. <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , 1995, 46, 425-441.	2.3	10
244	Gait deficiencies associated with peripheral artery disease are different than chronic obstructive pulmonary disease. <i>Gait and Posture</i> , 2017, 57, 258-264.	1.4	10
245	The COPD Biomarkers Qualification Consortium Database: Baseline Characteristics of the St George's Respiratory Questionnaire Dataset. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2017, 4, 108-119.	0.7	10
246	Socioeconomic Status as a Determinant of Health Status Treatment Response in COPD Trials. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2017, 4, 146-154.	0.7	10
247	Induction of fibronectin gene expression by transforming growth factor beta-1 is attenuated in bronchial epithelial cells by ADP-ribosyltransferase inhibitors. <i>Journal of Cellular Physiology</i> , 1992, 152, 274-280.	4.1	9
248	Effect of budesonide on fibroblast-mediated collagen gel contraction and degradation. <i>Journal of Inflammation Research</i> , 2013, 6, 25.	3.5	9
249	Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β_2 -agonist fixed-dose combination: Rationale and study design. <i>International Journal of COPD</i> , 2016, Volume 11, 1921-1928.	2.3	9
250	The Association Between Dietary Intake and Phenotypical Characteristics of COPD in the ECLIPSE Cohort. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2014, 1, 115-124.	0.7	9
251	Pulmonary Complications of Transplantation. <i>Annual Review of Medicine</i> , 1992, 43, 425-435.	12.2	8
252	Effect of tiotropium on night-time awakening and daily rescue medication use in patients with COPD. <i>Respiratory Research</i> , 2016, 17, 27.	3.6	8

#	ARTICLE	IF	CITATIONS
253	Current smoking with or without chronic bronchitis is independently associated with goblet cell hyperplasia in healthy smokers and COPD subjects. <i>Scientific Reports</i> , 2020, 10, 20133.	3.3	8
254	Electronic cigarette extract induced toxic effect in iPSC-derived cardiomyocytes. <i>BMC Cardiovascular Disorders</i> , 2020, 20, 357.	1.7	8
255	Longitudinal Imaging-Based Clusters in Former Smokers of the COPD Cohort Associate with Clinical Characteristics: The SubPopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS). <i>International Journal of COPD</i> , 2021, Volume 16, 1477-1496.	2.3	8
256	Responder Analyses for Treatment Effects in COPD Using the St George's Respiratory Questionnaire. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2017, 4, 120-127.	0.7	8
257	New therapeutic drugs in the management of chronic obstructive pulmonary disease. <i>Current Opinion in Pulmonary Medicine</i> , 2002, 8, 106-111.	2.6	7
258	Pathogenesis of COPD. <i>Clinical Cornerstone</i> , 2003, 5, 11-16.	0.7	7
259	Antiinflammatory Therapies Other Than Corticosteroids. <i>Proceedings of the American Thoracic Society</i> , 2004, 1, 282-287.	3.5	7
260	PKC δ mediates thrombin-augmented fibroblast-mediated collagen gel contraction. <i>Biochemical and Biophysical Research Communications</i> , 2008, 369, 1199-1203.	2.1	6
261	Co-Morbidity Patterns Identified Using Latent Class Analysis of Medications Predict All-Cause Mortality Independent of Other Known Risk Factors: The COPD Gene Study. <i>Clinical Epidemiology</i> , 2020, Volume 12, 1171-1181.	3.0	6
262	Smaller Left Ventricle Size at Noncontrast CT Is Associated with Lower Mortality in COPD Gene Participants. <i>Radiology</i> , 2020, 296, 208-215.	7.3	6
263	COPD Patients Have a Restricted Breathing Pattern That Persists with Increased Metabolic Demands. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2020, 17, 245-252.	1.6	6
264	Forced Expiratory Flow at 25%-75% Links COPD Physiology to Emphysema and Disease Severity in the SPIROMICS Cohort. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2022, 9, 111-121.	0.7	6
265	IL-4 and IL-13 Induce Chemotaxis of Human Foreskin Fibroblasts, But Not Human Fetal Lung Fibroblasts. <i>Inflammation</i> , 2004, 28, 33-37.	3.8	5
266	Challenges and Opportunities for Combination Therapy in Chronic Obstructive Pulmonary Disease. <i>Proceedings of the American Thoracic Society</i> , 2005, 2, 391-393.	3.5	5
267	Epithelial Cells and Fibroblasts. <i>Novartis Foundation Symposium</i> , 2008, , 104-119.	1.1	5
268	Antiproteases Attenuate the release of Neutrophil Chemotactic Activity from Bronchial Epithelial Cells Induced by Smoke. <i>Experimental Lung Research</i> , 1996, 22, 1-19.	1.2	4
269	Anticholinergic bronchodilators in combination. <i>Expert Opinion on Pharmacotherapy</i> , 2000, 1, 1281-1287.	1.8	4
270	Heme metabolism genes Downregulated in COPD Cachexia. <i>Respiratory Research</i> , 2020, 21, 100.	3.6	4

#	ARTICLE	IF	CITATIONS
271	What's New with the St George's Respiratory Questionnaire and Why Do We Care?. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2017, 4, 79-82.	0.7	4
272	COPDCompEx: A novel composite endpoint for COPD exacerbations to enable faster clinical development. Respiratory Medicine, 2020, 173, 106175.	2.9	4
273	Budesonide and risk of pneumonia " Authors' reply. Lancet, The, 2009, 374, 2051-2052.	13.7	3
274	Location, location, location: studying anatomically comparable airways is highly relevant to understanding COPD. Thorax, 2014, 69, 1049-1050.	5.6	3
275	Rationale for a Redundant Formulary. The Hawthorne Effect and the Art of Medicine. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 1224-1225.	5.6	3
276	Turning subtypes into disease axes to improve prediction of COPD progression. Thorax, 2019, 74, 906-909.	5.6	3
277	Improving the evaluation of COPD exacerbation treatment effects by accounting for early treatment discontinuations: a post-hoc analysis of randomized clinical trials. Respiratory Research, 2020, 21, 158.	3.6	3
278	The COPD Foundation Pocket Consultant Guide. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2014, 1, 83-87.	0.7	3
279	Introducing the New COPD Pocket Consultant Guide App: Can A Digital Approach Improve Care? A Statement of the COPD Foundation. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2019, 6, 210-220.	0.7	3
280	Pathogenesis of chronic obstructive pulmonary disease. Pneumonologia I Alergologia Polska, 2011, 79, 132-8.	0.6	3
281	Lessons from Multidisciplinary Cross-Fertilization: Chronic Obstructive Pulmonary Disease, Lung Cancer, and Heart Disease. Proceedings of the American Thoracic Society, 2008, 5, 865-868.	3.5	2
282	Pathophysiology of COPD. , 2009, , 425-442.		2
283	Baseline Severity as Predictor of Change in St George's Respiratory Questionnaire Scores in Trials of Long-acting Bronchodilators with COPD Patients. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2017, 4, 107-114.	1.0784314	2
284	Waiting for Actionable Evidence: Roflumilast or Azithromycin?. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2022, 9, 1-3.	0.7	2
285	Treatment for Stable COPD. , 2009, , 823-836.		1
286	Interview - Chronic obstructive pulmonary disease: current & future directions. Therapy: Open Access in Clinical Medicine, 2009, 6, 791-793.	0.2	1
287	PGE2 Desensitizes β_2 -Agonist Effect on Human Lung Fibroblast-Mediated Collagen Gel Contraction through Upregulating PDE4. Mediators of Inflammation, 2013, 2013, 1-9.	3.0	1
288	The St. George's Respiratory Questionnaire Appendix to the Food and Drug Administration Draft Guidance on COPD. Chest, 2017, 152, 914-916.	0.8	1

#	ARTICLE	IF	CITATIONS
289	COPD9USA June 2015. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2015, 2, 343-366.	0.7	1
290	Wireless, Battery Free Wearable Electronic Nose. , 2022, , .		1
291	Morphological Study of Bovine Lung Grafted into the Hamster Cheek Pouch. Experimental Lung Research, 1992, 18, 145-154.	1.2	0
292	Upper Airway Diseases. , 0, , 513-527.		0
293	Foreword. Proceedings of the American Thoracic Society, 2008, 5, 795-795.	3.5	0
294	Republished editorial: Hypothesis: in COPD, a pound of cure may be better than an ounce of prevention. Postgraduate Medical Journal, 2011, 87, 793-794.	1.8	0
295	Preface. Medical Clinics of North America, 2012, 96, xi-xii.	2.5	0
296	Efficacy of an inhaled corticosteroid/long-acting β_2 -agonist combination in symptomatic COPD patients in GOLD groups B and D. European Respiratory Journal, 2015, 46, 255-258.	6.7	0
297	Response. Chest, 2020, 158, 2232.	0.8	0
298	Outcomes consequent to "early" COPD for interventional studies. European Respiratory Journal, 2020, 55, 1902380.	6.7	0
299	Receptor subtypes involved in lung fibroblast-mediated collagen gel contraction stimulated by lysophosphatidic acid and serum. FASEB Journal, 2008, 22, 728.9.	0.5	0
300	Pharmacological Therapy: Novel Approaches. , 2011, , 129-147.		0
301	Inhibition of MicroRNA 146a Expression in Lung Fibroblasts by Fluticasone Propionate, Salmeterol Xinafoate, and Related Agents. FASEB Journal, 2015, 29, 619.12.	0.5	0
302	Response. Chest, 2022, 161, e249-e250.	0.8	0